Articles and Videos
Loading...
January 7, 2022
InMed Pharmaceuticals (NASDAQ: INM) “Addressing The Increasing Demand For Rare Cannabinoids”
InMed's CEO, Eric A. Adams, and BayMedica's SVP and GM, Shane Johnson, and VP of Commercial Operations, Chris Meiering, join Tribe Public's Webinar "Addressing the...
Source: Tribe Public
January 6, 2022
Lytham Partners Winter Conference 2021 – InMed Talks About Addressing the Demand for Rare Cannabinoids
Lytham Partners' Robert Blum speaks with InMed Pharmaceuticals CEO, Eric A. Adams, and BayMedica's VP Commercial Operations, Chris Meiering. In this video, Eric and Chris...
Source: Lytham Partners
December 21, 2021
The Dales Report:InMed Pharmaceuticals: 2022 Looking Bright With Recent Acquisition Of BayMedica
The Dales Report Host Shadd Dales spoke with InMed CEO, Eric A. Adams, about plans for 2022. Excerpt from The Dales Report: Listed on the...
Source: The Dales Report
December 20, 2021
InMed Welcomes the BayMedica Team – Meet Research Scientist Dr. James Craig!
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. James Craig, one of our Research Scientists at...
December 15, 2021
InMed Welcomes the BayMedica Team – Welcome Dr. Jim Kealey, VP of Synthetic Biology
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Jim Kealey, our VP of Synthetic Biology. Jim...
Source: Edison TV
December 8, 2021
InMed Welcomes the BayMedica Team! Welcome Dr. Charles Marlowe, VP of Chemistry
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Charles Marlowe, our VP of Chemistry. Chuck talks...
Source: Edison TV
